Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Sitaxentan in Japanese PAH Patients
NCT01210443Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2010
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sitaxsentan in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Started Nov 2010; status: terminated.
02
Drugs
sitaxsentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01210443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01210443.